mTatt provides painless, sub‑millimeter microneedle‑applied fluorescent microtattoos that continuously sense biomarkers in interstitial fluid. The tattoos are read with a smartphone or low‑cost reader, sending real‑time data to a secure cloud dashboard for remote monitoring by patients and clinicians.
Funding
Funding not disclosed
Founders
Product
Problem
Many health conditions require regular biomarker testing, which typically involves painful blood draws and frequent clinic visits. This process can be inconvenient, costly, and discourages consistent monitoring, especially for patients managing chronic diseases at home.
Solution
mTatt offers fluorescent microtattoos that are applied to the skin using sub‑millimeter microneedles, providing a painless, transdermal method for continuous health monitoring. The microtattoos contain fluorescent sensors that react to specific biomarkers in interstitial fluid, generating optical signals that can be read with a simple handheld or smartphone‑based reader. Because the tattoos remain in the skin, they enable ongoing measurement without repeated sampling, allowing users to track multiple health parameters from the comfort of their home. Data are transmitted to a secure cloud platform where trends can be visualized and shared with healthcare providers for remote assessment and timely intervention.
Target Audience
Primary users are individuals managing chronic conditions such as diabetes or metabolic disorders, as well as tele‑health providers and remote monitoring programs seeking non‑invasive, at‑home diagnostic tools.
Features
- Sub‑1 mm microneedle delivery system that inserts the microtattoo painlessly and without drawing blood
- Fluorescent sensor array tuned to detect a range of biomarkers (e.g., glucose, lactate, electrolytes)
- Optical readout compatible with standard smartphone cameras or dedicated low‑cost readers
- Continuous, real‑time monitoring with data automatically uploaded to a cloud dashboard
- Secure data sharing options for clinicians to review trends and adjust treatment plans remotely